Percutaneous Transluminal Angioplasty (PTA) Balloons Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Standard PTA Balloons, High-Pressure PTA Balloons, Scoring Balloons, Cutting Balloons, Drug-Coated Balloons (DCB), and Cylindrical Balloons), By Material (Polyethylene Terephthalate (PET), Polyurethane, Nylon, and Others), By Application (Peripheral Artery Disease (PAD), Renal Artery Angioplasty, Visceral Artery Stenosis, Venous Angioplasty, AV Fistula & Grafts, and Others), By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Catheterization Laboratories, and Specialty Clinics), and Region Forecast 2020-2031

Percutaneous Transluminal Angioplasty (PTA) Balloons Market size was valued at US$ 3,052.0 million in 2024 and is projected to reach US$ 5,367.7 million by 2031, growing at a CAGR of 8.4% from 2025-2031. Moreover, in the USA, the market is expected to grow at a CAGR of 8.8% from 2025-2031.

Percutaneous Transluminal Angioplasty (PTA) balloons are specialized catheter-based devices used to dilate stenosed or occluded blood vessels through balloon inflation, compressing atherosclerotic plaque against the vessel wall and restoring blood flow. Widely applied in peripheral artery disease (PAD), renal and visceral artery stenosis, and arteriovenous fistula maintenance, PTA balloons offer a minimally invasive alternative to open surgery. They vary by compliance, pressure tolerance, and design, including non-compliant high-pressure balloons for resistant lesions, scoring and cutting balloons for controlled plaque modification, and drug-coated balloons (DCBs) delivering antiproliferative agents to reduce restenosis. Balloon materials such as PET, Nylon, and Polyurethane influence flexibility, expansion control, and suitability for arteries or veins. Advantages include short recovery, repeatability, and compatibility with stents. However, the market faces several challenges, including elastic recoil of the vessel after deflation, risk of vessel dissection, restenosis due to neointimal hyperplasia, limited efficacy in heavily calcified lesions, and the need for careful procedural planning to avoid complications.

Key Takeaways

• PTA balloons are a preferred minimally invasive solution for treating peripheral, renal, and coronary artery stenosis.
• Continuous development of drug-coated, high-pressure, and specialty balloons enhances procedural precision and safety.
• Rising PAD prevalence, healthcare infrastructure expansion, and increased awareness of vascular diseases support sustained market growth.

Key Developments

• In October 2025, Cagent Vascular announced the commercial launch of the Serranator PTA Serration Balloon Catheter in 7.0 mm and 8.0 mm diameters. This expansion brings serration technology to larger vessels, including the iliac and superficial femoral arteries.
• In September 2025, Mozarc Medical announced a strategic collaboration with DK Medical Technology to exclusively distribute DK MedTech’s DKutting™ PTA Scoring Balloon and DKaptain™ PTA High Pressure Balloon in the U.S., aiming to enhance dialysis vascular access management.
• In May 2025, Boston Scientific launched the Sterling SL Balloon Catheter, designed specifically for below-the-knee arteries. It features a low tip profile, excellent deliverability, and rapid deflation time, expanding the company's line of low-profile peripheral angioplasty balloon catheters.
• In April 2025, Medico’s Hirata launched the Luminor 18RX Paclitaxel-Eluting PTA Balloon, approved for treating de novo or non-stent restenosis lesions in the superficial femoral and proximal popliteal arteries.
• In April 2025, Cagent Vascular partnered with 3comma to serve as the exclusive international distributor in the European Union and Middle East and North Africa markets for Cagent Vascular’s Serranator PTA devices, aiming to expedite adoption in these regions.
• In February 2025, BrosMed and Cordis signed an agreement for the exclusive distribution of BrosMed’s next-generation drug-coated balloon, VaSecure™, in the China market, expanding their presence in the region.
• In February 2025, Teleflex announced the acquisition of Separation and Vascular Intervention, including balloon catheter and complex catheter technologies, with the deal anticipated to close by the end of the third quarter of 2025.

Percutaneous Transluminal Angioplasty Pta Balloons Market Segmentation

Based on the Product Type

• Standard PTA Balloons
• High-Pressure PTA Balloons
• Scoring Balloons
• Cutting Balloons
• Drug-Coated Balloons (DCB)
• Cylindrical Balloons

Drug-Coated Balloons (DCB) are a dominating segment in the market. They combine mechanical dilation with localized drug delivery, releasing antiproliferative agents to the vessel wall, significantly reducing restenosis rates without leaving a permanent implant. Their efficacy in both coronary and peripheral interventions drives strong clinical adoption globally.

Based on the Material

• Polyethylene Terephthalate (PET)
• Polyurethane
• Nylon
• Others

Polyethylene Terephthalate (PET) is the dominating material segment in PTA balloons due to its high tensile strength, excellent dimensional stability, and resistance to deformation. These properties ensure precise and controlled expansion, making PET balloons ideal for a wide range of vascular interventions, including peripheral and coronary angioplasty procedures.

Based on the Application

• Peripheral Artery Disease (PAD)
• Renal Artery Angioplasty
• Visceral Artery Stenosis
• Venous Angioplasty
• AV Fistula & Grafts
• Others

 The Peripheral Artery Disease (PAD) segment dominates the market, as it affects millions globally, particularly older adults. PTA balloons are widely used to dilate narrowed peripheral arteries, improve blood flow, and alleviate symptoms like claudication. Minimally invasive procedures and growing PAD prevalence drive strong demand in this segment.

Based on the End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Catheterization Laboratories
• Specialty Clinics

 The Hospitals segment dominates the market due to its advanced infrastructure, availability of trained interventional cardiologists, and high patient volumes. Hospitals offer comprehensive facilities for complex vascular procedures, including peripheral and coronary angioplasty, making them the preferred choice for PTA balloon interventions.